Novo Nordisk plans to invest 15.9 billion to Expansion in Hillerød, Denmark

Specifications:

Name:

Novo Nordisk plans to invest 15.9 billion to Expansion in Hillerød, Denmark

Location:

Denmark

Company:

NOVO NORDISK

Estimated Cost:

15.9 billion

Source:

https://www.novonordisk.com/

Introduction:

Novo Nordisk to expand an existing Active Pharmaceutical Ingredient (API) production facility in Denmark

Features:

The investment will be creating additional production capacity and increase Novo Nordisk’s ability to meet future market demands and be a key enabler for Novo Nordisk to develop its future clinical late-phase product portfolio.

The new facility which will be approximately 65,000m2 will be designed as a multi-product facility, with maximum flexibility to accommodate new processes and displaying state-of-the-art technology and working environment. As a future-proof and cost-effective facility, the construction will focus on delivering the highest quality to patients worldwide in an efficient and environmentally sustainable way. This will be done by designing optimal and compact process flows allowing a substantial reduction of water and energy consumption3.

Construction is underway and the facility is expected to start producing API by early 2029. This project is expected to create 340 new jobs when construction is completed, and the facility is fully equipped.